日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

IL-21/IL-21R signaling renders acute myeloid leukemia stem cells more susceptible to cytarabine treatment and CAR T cell therapy

IL-21/IL-21R信号通路使急性髓系白血病干细胞对阿糖胞苷治疗和CAR-T细胞疗法更加敏感。

Viviana Rubino ,Michelle Hüppi ,Sabine Höpner ,Luigi Tortola ,Noah Schnüriger ,Hugo Legenne ,Lea Taylor ,Svenja Voggensperger ,Irene Keller ,Remy Bruggman ,Marie-Noëlle Kronig ,Ulrike Bacher ,Manfred Kopf ,Adrian F Ochsenbein ,Carsten Riether

A phase 1b/2 study evaluating efficacy and safety of MP0250, a designed ankyrin repeat protein (DARPin) simultaneously targeting vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF), in combination with bortezomib and dexamethasone, in patients with relapsed or refractory multiple myeloma

一项 1b/2 期研究评估了 MP0250(一种设计用于同时靶向血管内皮生长因子 (VEGF) 和肝细胞生长因子 (HGF) 的锚蛋白重复序列蛋白 (DARPin))联合硼替佐米和地塞米松治疗复发或难治性多发性骨髓瘤患者的疗效和安全性。

Knop, Stefan; Szarejko, Monika; Grząśko, Norbert; Bringhen, Sara; Trautmann-Grill, Karolin; Jurczyszyn, Artur; Vacca, Angelo; Khandanpour, Cyrus; Gamberi, Barbara; Pour, Ludek; Iversen, Katrine F; Stumpp, Michael T; Suter, Cosima; Dawson, Keith M; Zitt, Christof; Legenne, Philippe; Stavropoulou, Vaia; Fey, Martin F; Leupin, Nicolas; Goldschmidt, Hartmut

Efficacy and Safety of Ensovibep for Adults Hospitalized With COVID-19 : A Randomized Controlled Trial

Ensovibep治疗COVID-19住院成人患者的疗效和安全性:一项随机对照试验

Barkauskas, Christina; Mylonakis, Eleftherios; Poulakou, Garyfallia; Young, Barnaby E; Vock, David M; Siegel, Lianne; Engen, Nicole; Grandits, Greg; Mosaly, Nilima R; Vekstein, Andrew M; Rogers, Ralph; Shehadeh, Fadi; Kaczynski, Matthew; Mylona, Evangelia K; Syrigos, Konstantinos N; Rapti, Vasiliki; Lye, David C; Hui, Diong Shiau; Leither, Lindsay; Knowlton, Kirk U; Jain, Mamta K; Marines-Price, Rubria; Osuji, Alice; Overcash, J Scott; Kalomenidis, Ioannis; Barmparessou, Zafeiria; Waters, Michael; Zepeda, Karla; Chen, Peter; Torbati, Sam; Kiweewa, Francis; Sebudde, Nicholus; Almasri, Eyad; Hughes, Alyssa; Bhagani, Sanjay R; Rodger, Alison; Sandkovsky, Uriel; Gottlieb, Robert L; Nnakelu, Eriobu; Trautner, Barbara; Menon, Vidya; Lutaakome, Joseph; Matthay, Michael; Robinson, Philip; Protopapas, Konstantinos; Koulouris, Nikolaos; Kimuli, Ivan; Baduashvili, Amiran; Braun, Dominique L; Günthard, Huldrych F; Ramachandruni, Srikanth; Kidega, Robert; Kim, Kami; Hatlen, Timothy J; Phillips, Andrew N; Murray, Daniel D; Jensen, Tomas O; Padilla, Maria L; Accardi, Evan X; Shaw-Saliba, Katy; Dewar, Robin L; Teitelbaum, Marc; Natarajan, Ven; Laverdure, Sylvain; Highbarger, Helene C; Rehman, M Tauseef; Vogel, Susan; Vallée, David; Crew, Page; Atri, Negin; Schechner, Adam J; Pett, Sarah; Hudson, Fleur; Badrock, Jonathan; Touloumi, Giota; Brown, Samuel M; Self, Wesley H; North, Crystal M; Ginde, Adit A; Chang, Christina C; Kelleher, Anthony; Nagy-Agren, Stephanie; Vasudeva, Shikha; Looney, David; Nguyen, Hien H; Sánchez, Adriana; Weintrob, Amy C; Grund, Birgit; Sharma, Shweta; Reilly, Cavan S; Paredes, Roger; Bednarska, Agnieszka; Gerry, Norman P; Babiker, Abdel G; Davey, Victoria J; Gelijns, Annetine C; Higgs, Elizabeth S; Kan, Virginia; Matthews, Gail; Thompson, B Taylor; Legenne, Philippe; Chandra, Richa; Lane, H Clifford; Neaton, James D; Lundgren, Jens D

A Case of Sustained Tumor Regression With MP0274, a Novel DARPin Therapeutic Targeting Human Epidermal Growth Factor Receptor 2 Signaling, in Metastatic Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer After Prior Trastuzumab and Pertuzumab

MP0274是一种新型DARPin疗法,靶向人表皮生长因子受体2信号通路,可使转移性人表皮生长因子受体2阳性乳腺癌患者在接受曲妥珠单抗和帕妥珠单抗治疗后出现持续性肿瘤消退。

Fischer, Stefanie; Götze, Thorsten O; Omlin, Aurelius; Baird, Richard D; Dawson, Keith M; Zitt, Christof; Arany, Zita; Tresch, Gaby; Fiedler, Ulrike; Jeger, Simone; Fung, Samson; Legenne, Philippe; Leupin, Nicolas; Schneeweiss, Andreas; Fremd, Carlo

1130. Ensovibep antiviral activity in ambulatory patients with COVID-19 is independent of baseline anti-SARS-CoV-2 antibodies and exhibits minimal selective pressure – Results from the placebo-controlled EMPATHY trial

1130. Ensovibep 在 COVID-19 门诊患者中的抗病毒活性与基线抗 SARS-CoV-2 抗体无关,且选择性压力极小——来自安慰剂对照 EMPATHY 试验的结果

Baker, Danial E; Abrishamian, Luis; Bonten, Marc; Chandra, Richa; Elango, Damodaran Solai; Fustier, Pierre; Gedif, Kinfemichael; Goncalves, Susana; Igbinadolor, Awawu; Kingsley, Jeff; Knutson, Charles G; Kukkaro, Petra; Kumarasamy, Nagalingeswaran; Legenne, Philippe; Mekebeb-Reuter, Martha; Ramanathan, Krishnan; Reshetnyak, Evgeniya; Robinson, Michael; Rosa, Jennifer; Soergel, Marianne; Stavropoulou, Vaia; Stojcheva, Nina; Stumpp, Michael T; Tietz, Andreas; Zhao, Xiaojun; Zhang, Zhaojie